JPJuan Francisco Zazueta Pozos

Juan Francisco Zazueta Pozos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juan Francisco Zazueta Pozos has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Essential role of radiotherapy in NK/T-cell lymphoma: evidence from a single-center study in Mexico

    by Josheline Goretti Ramírez Jaramillo, Alonso Hernández Company, Gilberto Barranco Lampón, Juan Francisco Zazueta Pozos, Gerardo Santiago Jiménez, Lena Grissel Simental Legarda, Emmanuel Martínez Moreno, Humberto Baldemar Castellanos Sinco, José Eugenio Vázquez Meraz, Efreen Horacio Montaño Figueroa, et al.

  • Open Access

    COVID‐19 in a country with a very high prevalence of diabetes: The impact of admission hyperglycaemia on mortality

    by Carlos Martínez‐Murillo, Christian Ramos Peñafiel, Lourdes Basurto, Lourdes Balcázar‐Hernández, Karen Pellón, Eder Flores López, Beatriz Li Gómez, Mercedes Estefania Ledesma, Rodrigo Rivera Tapia, Elizabeth Madera Maldonado, et al.

    Aims: To evaluate the frequency of diabetes and admission hyperglycaemia in Mexican COVID‐19 patients, to describe the clinical and biochemical characteristics of patients with admission hyperglycaemia and to determinate the impact of diabetes and admission hyperglycaemia on COVID‐19 severity and mortality.Methods: A multicentric study was performed in 480 hospitalized patients with COVID‐19. Clinical and biochemical characteristics were evaluated in patients with admission hyperglycaemia and compared with non‐hyperglycaemic patients. The effect of diabetes and admission hyperglycaemia on severity and risk of death were evaluated.Results: Age was 50.7 ± 13.6 years; 68.3% were male. Some 48.5% (n = 233) had admission hyperglycaemia; 29% (n = 139) of these patients had pre‐existing diabetes. Patients with admission hyperglycaemia had more requirement of invasive mechanical ventilation (IMV), higher levels of urea, D‐dimer and neutrophil‐lymphocyte ratio (NLR), as well as lower lymphocyte count. An association between admission hyperglycaemia with IMV and D‐dimer with glucose was found. Age ≥50 years (OR 2.09; 95%CI 1.37–3.17), pre‐existing diabetes (OR 2.38; 95%CI 1.59–5.04) and admission hyperglycaemia (OR 8.24; 95%CI 4.74–14.32) were risk factors for mortality.Conclusions: Admission hyperglycaemia is presented in 48.5% of COVID‐19 patients. Diabetes and admission hyperglycaemia are associated with the severity of disease and mortality. This study shows the devastating conjunction of hyperglycaemia and COVID‐19.Clinical trial registration: Clinical characteristics of patients with COVID‐19, DI/20/204/04/41 (Hospital General de Mexico) and NR‐13‐2020 (Hospital Regional de Alta Especialidad Ixtapaluca).